Recipharm Launches Inhalation Offering

Recipharm has launched its inhalation offering to provide customers with a fully integrated service from early stage development through to commercial manufacturing.

Recipharm Inhalation Solutions offers pharmaceutical companies an outsourcing service for inhalation products, including metered dose inhalers (MDIs), dry powder inhalers (DPIs) and nasal sprays.

The offering follows the acquisition of Sanofi’s inhalation manufacturing business in Holmes Chapel, UK in June 2018, which specialized in the manufacture of inhalation drug products. The facility is supported by Recipharm’s inhalation development expertise in Research Triangle Park, NC.

Shabbir Mostafa, Global Key Account Director – Inhalations at Recipharm said, "Treatments for respiratory conditions are in high demand, making inhalation products a key growth area for our business. In addition to respiratory diseases, they are now being explored as alternative delivery routes to improve bioavailability and lower the risk of adverse effects, in treating for instance central nervous system conditions. This is making inhalation an interesting area for drug developers."

"The Recipharm team has a long history in inhalation drug product development and manufacturing. This heritage, combined with market demand, made the launch of Recipharm Inhalation Solutions a logical step for us."

Register as Visitor to CPhI China 2019!

-----------------------------------------------------------------------
Editor's Note:

To apply for becoming a contributor of En-CPhI.cn,

welcome to send your CV and sample works to us,

Email: Julia.Zhang@ubmsinoexpo.com.